About BioViva’s first gene therapy experiment against ageing

The news about BioViva’s first successful intervention on human ageing is not exactly news any more. When your post backlog is as long as mine is, you inevitably end up with some stale news that are still worth dropping a line.

Some months ago, the company BioViva made its first attempt to intervene on an aspect of human ageing through gene therapy. Specifically, the very company’s CEO, Elizabeth Parrish, ‘[…] received two of her own company’s experimental gene therapies: one to protect against loss of muscle mass with age, another to battle stem cell depletion responsible for diverse age-related diseases and infirmities.’

Long story short, as a consequence of the treatment, Parrish’s leukocytes’ telomeres seem to be longer than they usually are at her age. Data seems to indicate they’ve been ‘rejuvenated’ by 20 years.

However, one must understand this is an experiment with a sample size of one, and that BioViva’s CEO will have to be monitored for years to come to make sure the data is correct and there are no nasty side-effects. FightAging! has also voiced a slight skepticism, not so much in the reliability of the data, but rather on the actual correlation between age and telomere length.

I guess we can only wait and see.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s